Researchers report in the July 2000 issue of the Journal of Immunology that tetrahydrocannabinol (THC), the major psychoactive component of marijuana, can promote tumor growth by impairing the body's anti-tumor immunity system. While previous research has shown that THC can lower resistance to both bacterial and viral infections, this is the first time that its possible tumor-promoting activity has been reported.
A team of researchers at UCLA's Jonsson Cancer Center found in experiments in mice that THC limits immune response by increasing the availability of two forms (IL-10 and TGF-beta) of cytokine, a potent, tumor-specific, immunity suppresser.
The authors also suggest that smoking marijuana may be more of a cancer risk than smoking tobacco. The tar portion of marijuana smoke, compared to that of tobacco, contains higher concentrations of carcinogenic hydrocarbons, including benzapyrene, a key factor in promoting human lung cancer. And marijuana smoke deposits four times as much tar in the respiratory tract as does a comparable amount of tobacco, thus increasing exposure to carcinogens. Dr. Steven M. Dubinett, head of the research team that conducted the study, says, "What we already know about marijuana smoke, coupled with our new finding that THC may encourage tumor growth, suggests that regular use of marijuana may increase the risk of respiratory tract cancer and further studies will be needed to evaluate this possibility."
The UCLA researchers examined the effects of THC on the immune response to lung cancer in mice. Over a two-week period, the animals were injected four times per week with either THC or a saline solution. Fourteen days after the injections were started, murine Lewis lung cancer and line 1 alveolar cell cancer cells were implanted in the mice. The mice continued to receive THC or saline injections after the tumor cells were implanted, and tumor growth was assessed three times each week. To test the hypothesis that THC impairs tumor-specific immune system response, a group of mice with compromised immune systems was also studied.
The researchers found that in the mice with normal immune systems there was significant enhancement of tumor growth, but THC had no effect on tumor growth in the immunodeficient mice. The study also showed that when lymphocytes from the THC-treated mice were injected into untreated mice, the immune deficit was transferred and tumor growth was accelerated in the normal controls. Additionally, the UCLA research team demonstrated that when anti-IL-10 and anti-TGF-beta were administered, there was no acceleration of tumor growth in THC-treated mice. These results suggest that enhanced tumor growth is prompted by THC's ability to stimulate production of IL-10 and TGF-beta, which inhibits anti-tumor immune response.
The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports more than 85 percent of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to ensure the rapid dissemination of research information and its implementation in policy and practice. Fact sheets on the health effects of drugs of abuse and other topics can be ordered free of charge in English and Spanish by calling NIDA Infofax at 1-888-NIH-NIDA (644-6432) or 1-888-TTY-NIDA (889-6432) for the deaf. These fact sheets and further information on NIDA research and other activities can be found on the NIDA home page at http://www.drugabuse.gov. (thcrelease)
Journal
The Journal of Immunology